Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease
Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease
复制标题
DOI：
10.1007/s00380-011-0213-6
复制
发表时间：
2013-01-01
影响因子：
1.5
通讯作者：
Kihara, Yasuki
中科院分区：
文献类型：
--
作者：
Kurisu, Satoshi;Ishibashi, Ken;Kihara, Yasuki
用染色剂治疗后心血管事件的剩余风险部分可能是因为患者的n-3多不饱和脂肪酸（PUFA）水平较低。我们研究了强他汀类降脂治疗如何影响冠状动脉疾病患者血清PUFA水平。研究人群包括46名低密度脂蛋白（LDL）胆固醇超过100 mg/dl的冠状动脉疾病患者。降脂治疗采用强效他汀类药物，包括阿托伐他汀（n = 22）、瑞舒伐他汀（n = 9）或匹伐他汀（n = 15）。用气相色谱法测定血清PUFA水平。强他汀类药物降低了二同γ -亚麻酸（DGLA）和花生四烯酸（AA）含量之和（195 +/- 41 ~ 184 +/- 44 μ g/ml, P < 0.05），降低了二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）含量之和（233 +/- 71 ~ 200 +/- 72 μ g/ml, P < 0.001）。强他汀类药物的这些作用导致EPA和DHA水平之和与DGLA和AA水平之和之比显著降低（1.20 +/- 0.27 ~ 1.10 +/- 0.35,P < 0.05）。LDL胆固醇水平下降百分比与EPA和DHA水平下降百分比的总和呈极显著相关（r = 0.38, P < 0.01）。综上所述，我们的研究结果表明，在冠状动脉疾病患者中，强效他汀类药物降脂治疗主要是降低n-3 PUFAs与降低LDL胆固醇水平成比例。
Residual risk of cardiovascular events after treatment with stain might be explained in part because patients have low levels of n-3 polyunsaturated fatty acids (PUFA). We examined how lipid-lowering therapy with strong statin affected serum PUFA levels in patients with coronary artery disease. The study population consisted of 46 patients with coronary artery disease whose low-density lipoprotein (LDL) cholesterol was more than 100 mg/dl. Lipid-lowering therapy was performed with a strong statin including atorvastatin (n = 22), rosuvastatin (n = 9) or pitavastatin (n = 15). Serum PUFA levels were determined by gas chromatography. The treatment with strong statin decreased the sum of dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA) levels (195 +/- 41 to 184 +/- 44 mu g/ml, P < 0.05) as well as the sum of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels (233 +/- 71 to 200 +/- 72 mu g/ml, P < 0.001). These effects of strong statin resulted in a significant decrease in ratio of the sum of EPA and DHA levels to the sum of DGLA and AA levels (1.20 +/- 0.27 to 1.10 +/- 0.35, P < 0.05). The percent decrease in the LDL cholesterol level correlated significantly with that in the sum of EPA and DHA levels (r = 0.38, P < 0.01). In conclusion, our results showed that lipid-lowering therapy with strong statin mainly reduced n-3 PUFAs in proportion to the decrease in the LDL cholesterol level in patients with coronary artery disease.